Informations:
Erreur:
ID
13154
Description
A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00559091
Lien
https://clinicaltrials.gov/show/NCT00559091
Mots-clés
Versions (1)
- 20/01/2016 20/01/2016 -
Détendeur de droits
CC BY-NC 3.0
Téléchargé le
20 janvier 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Acute Myelocytic Leukemia NCT00559091
Eligibility Acute Myelocytic Leukemia NCT00559091
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myelocytic Leukemia NCT00559091
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
AML diagnosis
Item
a diagnosis of acute myeloid leukemia (aml), either m4 or m5 subtype de novo or resulting from a transformation from mds or a myeloproliferative disorder.
boolean
C0023467 (UMLS CUI [1])
patients with aml who (a) have failed primary therapy -defined as failing two induction chemotherapies, (b) have relapsed or (c) are not suitable for intensive induction chemotherapy will be eligible. or
Item
patients with aml who (a) have failed primary therapy -defined as failing two induction chemotherapies, (b) have relapsed or (c) are not suitable for intensive induction chemotherapy will be eligible. or
boolean
C0023467 (UMLS CUI [1])
AML blast crisis from CML
Item
patients with aml blast crisis from cml if they are not suitable candidates for intensive induction chemotherapy or have failed imatinib mesylate or
boolean
C0023474 (UMLS CUI [1])
secondary aml after mds
Item
patients with secondary aml after mds if they are not suitable candidates for intensive induction chemotherapy.
boolean
C3463824 (UMLS CUI [1])
ECOG performance status
Item
ecog 0,1,2, or 3
boolean
C1520224 (UMLS CUI [1])
life expectancy
Item
life expectancy > 12 weeks.
boolean
C0023671 (UMLS CUI [1])
renal and hepatic function
Item
adequate renal and hepatic function
boolean
C0232804 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232741 (UMLS CUI [2])
uncontrolled central nervous system involvement by aml
Item
uncontrolled central nervous system involvement by aml
boolean
C3714787 (UMLS CUI [1])
NYHA
Item
active cardiovascular disease as defined by nyha class iii-iv categorization.
boolean
C1275491 (UMLS CUI [1])
intercurrent illness or medical condition precluding safe administration of ribavirin
Item
intercurrent illness or medical condition precluding safe administration of ribavirin.
boolean
C0035525 (UMLS CUI [1])
received any previous therapy within 28 days prior to study entry.hydrea is permitted but must be stopped 7 days prior to starting study drug
Item
received any previous therapy within 28 days prior to study entry.hydrea is permitted but must be stopped 7 days prior to starting study drug.
boolean
C0020402 (UMLS CUI [1])
HIV
Item
known infection with hiv.
boolean
C0019682 (UMLS CUI [1])